CJC-1295 w/o DAC + Ipamorelin 10MG

CJC-1295 (without DAC) combined with Ipamorelin is a peptide blend formulated for research applications involving growth hormone regulation. CJC-1295 (w/o DAC) is a modified analog of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue that interacts with ghrelin receptors. Together, this combination is studied in controlled laboratory environments for its potential synergistic effects on stimulating endogenous growth hormone release through complementary pathways.

Research Context

This peptide combination is recognized in scientific research for its dual mechanism of action. CJC-1295 (w/o DAC) targets GHRH receptors in the pituitary to promote growth hormone release, while Ipamorelin selectively binds to ghrelin (GHS-R1a) receptors. The concurrent activation of these pathways makes this blend a focal point in studies investigating enhanced pulsatile growth hormone secretion and endocrine system modulation.

Research Overview

CJC-1295 (w/o DAC) was developed as a shorter-acting GHRH analog designed to mimic natural hormone signaling patterns without extended half-life modifications. Ipamorelin, as a pentapeptide, selectively stimulates growth hormone release through ghrelin receptor activation. Experimental studies have explored the combined use of these peptides to evaluate potential synergistic interactions, where activation of both GHRH and GHS pathways may enhance growth hormone output while maintaining physiological release patterns.

Key Research Focus Areas

• Synergistic Growth Hormone Release: The combination is studied for its potential to enhance endogenous growth hormone secretion through dual receptor activation.
• Endocrine Pathway Modulation: Research explores how simultaneous stimulation of GHRH and ghrelin receptors influences hormonal signaling.
• Pulsatile Hormone Secretion: Investigations focus on maintaining natural growth hormone release patterns in experimental models.
• Receptor Interaction Studies: The blend is used to study the interaction between GHRH and GHS receptor pathways in controlled environments.

Important Disclaimers

CJC-1295 w/o DAC + Ipamorelin 10MG is intended for use exclusively in academic and institutional research environments. This product is not intended for therapeutic, diagnostic, cosmetic, or human/animal consumption. It is critical that all researchers adhere to local regulatory guidelines, including proper handling protocols and documentation requirements. Handling peptides may present risks associated with exposure, storage, and experimental contamination. Always consult with institutional safety officers and follow established laboratory protocols.

For research use only. Not for human or animal consumption.